RU2013113188A - Комбинированное лечение дерматологических состояний - Google Patents
Комбинированное лечение дерматологических состояний Download PDFInfo
- Publication number
- RU2013113188A RU2013113188A RU2013113188/15A RU2013113188A RU2013113188A RU 2013113188 A RU2013113188 A RU 2013113188A RU 2013113188/15 A RU2013113188/15 A RU 2013113188/15A RU 2013113188 A RU2013113188 A RU 2013113188A RU 2013113188 A RU2013113188 A RU 2013113188A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- brimonidine
- oxymetazoline
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38726810P | 2010-09-28 | 2010-09-28 | |
| US61/387,268 | 2010-09-28 | ||
| US13/232,139 | 2011-09-14 | ||
| US13/232,139 US20120076738A1 (en) | 2010-09-28 | 2011-09-14 | Combination treatment for dermatological conditions |
| PCT/US2011/053455 WO2012050831A2 (en) | 2010-09-28 | 2011-09-27 | Combination treatment for dermatological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013113188A true RU2013113188A (ru) | 2014-11-10 |
Family
ID=45870879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013113188/15A RU2013113188A (ru) | 2010-09-28 | 2011-09-27 | Комбинированное лечение дерматологических состояний |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20120076738A1 (https=) |
| EP (1) | EP2621498A4 (https=) |
| JP (1) | JP2013542930A (https=) |
| KR (1) | KR20140056129A (https=) |
| CN (1) | CN103354744A (https=) |
| AU (1) | AU2011314151A1 (https=) |
| CA (1) | CA2821993A1 (https=) |
| MX (1) | MX2013003639A (https=) |
| RU (1) | RU2013113188A (https=) |
| WO (1) | WO2012050831A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130079312A1 (en) * | 2011-09-28 | 2013-03-28 | Elorac, Ltd. | Method of Treating Hair Loss Due to Systemic Chemotherapy |
| BR112015027984A2 (pt) * | 2013-05-06 | 2017-09-05 | Allergan Inc | Agonistas alfa adrenérgicos para o tratamento de lesão de tecido |
| US20150258011A1 (en) * | 2014-03-15 | 2015-09-17 | Marty Richard Hunter | Treatment of keratinized tissues |
| KR20170132725A (ko) * | 2015-02-24 | 2017-12-04 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 안구 건조 질환 및 다른 안과 질환을 치료하기 위한 방법 및 조성물 |
| EP3319607A4 (en) | 2015-07-09 | 2019-04-03 | Galderma S.A. | METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY |
| RU2605687C1 (ru) * | 2015-09-21 | 2016-12-27 | Ирина Николаевна Усманова | Способ лечения рецидивирующего афтозного стоматита |
| EP3624773A4 (en) | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | OPHTHALMIC COMPOSITIONS AND METHOD OF USE |
| KR20210011926A (ko) * | 2018-04-18 | 2021-02-02 | 포르테 서브시디어리, 인크. | 피부 상태의 치료를 위한 조성물 |
| BR112021003452A2 (pt) * | 2018-08-29 | 2021-05-18 | Cellix Bio Private Limited | composto e composição farmacêutica |
| WO2020065085A1 (fr) * | 2018-09-28 | 2020-04-02 | Galderma Research & Development | Composition pharmaceutique comprenant de la brimonidine, et ses utilisations |
| WO2020144546A1 (en) * | 2019-01-12 | 2020-07-16 | Cellix Bio Private Limited | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
| WO2020222192A1 (en) * | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| EP3962478A1 (en) * | 2019-05-01 | 2022-03-09 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| JP4955543B2 (ja) * | 2004-05-25 | 2012-06-20 | サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド | 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法 |
| WO2009017705A1 (en) * | 2007-07-27 | 2009-02-05 | Galderma Laboratories L.P. | Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging |
| JP5670196B2 (ja) * | 2007-11-16 | 2015-02-18 | バイセプト セラピューティクス、インク． | 紫斑を治療する組成物および方法 |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| WO2012001064A2 (en) * | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| PH12014500783A1 (en) * | 2011-10-19 | 2014-05-12 | Galderma Sa | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
-
2011
- 2011-09-14 US US13/232,139 patent/US20120076738A1/en not_active Abandoned
- 2011-09-27 CN CN2011800470603A patent/CN103354744A/zh active Pending
- 2011-09-27 EP EP11833012.5A patent/EP2621498A4/en not_active Withdrawn
- 2011-09-27 RU RU2013113188/15A patent/RU2013113188A/ru not_active Application Discontinuation
- 2011-09-27 MX MX2013003639A patent/MX2013003639A/es unknown
- 2011-09-27 KR KR1020137010903A patent/KR20140056129A/ko not_active Ceased
- 2011-09-27 WO PCT/US2011/053455 patent/WO2012050831A2/en not_active Ceased
- 2011-09-27 JP JP2013531721A patent/JP2013542930A/ja active Pending
- 2011-09-27 AU AU2011314151A patent/AU2011314151A1/en not_active Abandoned
- 2011-09-27 CA CA2821993A patent/CA2821993A1/en not_active Abandoned
-
2013
- 2013-12-10 US US14/101,464 patent/US20140094470A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,544 patent/US20150313895A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011314151A1 (en) | 2013-04-11 |
| US20150313895A1 (en) | 2015-11-05 |
| JP2013542930A (ja) | 2013-11-28 |
| WO2012050831A3 (en) | 2012-06-14 |
| KR20140056129A (ko) | 2014-05-09 |
| MX2013003639A (es) | 2013-09-16 |
| EP2621498A2 (en) | 2013-08-07 |
| US20120076738A1 (en) | 2012-03-29 |
| CN103354744A (zh) | 2013-10-16 |
| EP2621498A4 (en) | 2014-04-09 |
| CA2821993A1 (en) | 2012-04-19 |
| WO2012050831A2 (en) | 2012-04-19 |
| US20140094470A1 (en) | 2014-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013113188A (ru) | Комбинированное лечение дерматологических состояний | |
| JP2013542930A5 (https=) | ||
| RU2013113184A (ru) | Комбинированное лечение розацеа | |
| JOP20230113A1 (ar) | مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 | |
| AU2010313643B2 (en) | Methods of treating or preventing acute erythema | |
| EA201890218A1 (ru) | Ретиноидные композиции для местного применения | |
| MX392440B (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| JP2013538853A5 (https=) | ||
| AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
| EP2887928B1 (en) | Retinoids and use thereof | |
| RU2012124904A (ru) | КОМБИНАЦИЯ АГОНИСТА α2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И НЕСТЕРОИДНОГО ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ВОСПАЛИТЕЛЬНОГО ПОРАЖЕНИЯ КОЖИ | |
| RU2012122241A (ru) | Птеростилбен (pter) для применения в профилактике и/или лечении кожных заболеваний, повреждений или травм | |
| RU2014150505A (ru) | Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды | |
| AR065317A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
| RU2016106377A (ru) | Способ лечения утолщения кожи | |
| MX2014014818A (es) | Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel. | |
| WO2013103924A3 (en) | Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions | |
| WO2013182998A4 (en) | Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes | |
| BR112015027569A2 (pt) | compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß | |
| US20150093445A1 (en) | Formulations and methods for treatment of acne and inflammatory skin conditions | |
| CL2024003959A1 (es) | Formulaciones tópicas de benzimidazol y métodos para su uso en el tratamiento de dermatosis inflamatorias. | |
| RU2014122758A (ru) | Фармацевтические составы для лечения заболеваний и состояний кожи, содержащие 7-(1н-имидазол-4-илметил)-5,6,7,8-тетрагидрохинолин | |
| JP2014533271A5 (https=) | ||
| AR094027A1 (es) | Formulaciones topicas que contienen pidotimod |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161027 |